Pfizer Inc. $PFE Stock Sold by International Assets Investment Management LLC

Key Points

• International Assets Investment Management cut its Pfizer position by 33.9% in the third quarter, selling 55,504 shares; it retained 108,185 shares valued at about $3.1 million.
• Pfizer’s latest quarterly results beat estimates, with EPS of $0.87 versus $0.74 expected and revenue of $16.58 billion versus $15.85 billion expected; the company also raised its 2026 earnings outlook, though margin pressure remains a concern.
• Analysts remain mixed, with a consensus Hold rating and an average price target of $30.39. Pfizer shares opened at $29.38, and the company declared a $0.43 quarterly dividend, equivalent to a 5.9% annualized yield.

International Assets Investment Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 108,185 shares of the biopharmaceutical company's stock after selling 55,504 shares during the period. International Assets Investment Management LLC's holdings in Pfizer were worth $3,085,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC grew its stake in Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 509 shares during the period. Keb Asset Management LLC purchased a new position in Pfizer during the second quarter valued at $26,000. Field & Main Bank purchased a new position in Pfizer during the second quarter valued at $27,000. Bullseye Investment Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $28,000. Finally, Timbuktu Capital Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $29,000. Institutional investors own 68.36% of the company's stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Scotiabank lifted their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a "sector outperform" rating in a research report on Wednesday. HSBC boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 9th. Finally, Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Six research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $30.39.

Pfizer Trading Down 1.7%

Pfizer stock opened at $29.38 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.96 and a debt-to-equity ratio of 0.67. The business's fifty day simple moving average is $28.74 and its two-hundred day simple moving average is $26.90. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $31.44. The company has a market capitalization of $167.47 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 1.94 and a beta of 0.31.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the company earned $0.87 earnings per share. The company's revenue was down .4% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is currently 245.71%.

Pfizer Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.